Compare TWIN & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWIN | LCTX |
|---|---|---|
| Founded | 1918 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.7M | 388.6M |
| IPO Year | 1994 | 1996 |
| Metric | TWIN | LCTX |
|---|---|---|
| Price | $16.64 | $1.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 65.5K | ★ 1.4M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.76 | N/A |
| Revenue | ★ $340,738,000.00 | $14,556,000.00 |
| Revenue This Year | $10.79 | $109.40 |
| Revenue Next Year | $8.43 | N/A |
| P/E Ratio | $9.09 | ★ N/A |
| Revenue Growth | 15.45 | ★ 53.24 |
| 52 Week Low | $7.06 | $0.64 |
| 52 Week High | $19.67 | $2.09 |
| Indicator | TWIN | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.32 | 41.10 |
| Support Level | $14.38 | $1.14 |
| Resistance Level | $18.95 | $1.31 |
| Average True Range (ATR) | 1.24 | 0.08 |
| MACD | -0.20 | 0.00 |
| Stochastic Oscillator | 37.77 | 34.48 |
Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.